Literature DB >> 23227278

The amyloidoses: clinical features, diagnosis and treatment.

Kelty R Baker1, Lawrence Rice.   

Abstract

Amyloidosis is a rare disorder in which insoluble amyloid proteins are deposited in body organs, causing abnormal protein build-up in tissues and eventually leading to organ dysfunction and death. It affects less than 200,000 people in the United States, classifying it as a rare disease according to the National Institutes of Health. Definitive determination of the underlying protein is critical since prognosis and treatment of amyloidosis can vary widely depending on the responsible protein. The following paper describes the various types and clinical features of amyloidosis and provides an overview of current diagnostic tools and therapies.

Entities:  

Keywords:  AL amyloidosis; amyloidoses; hematopoietic stem cell transplantation; light chain amyloidosis; multiple myeloma

Mesh:

Substances:

Year:  2012        PMID: 23227278      PMCID: PMC3487569          DOI: 10.14797/mdcj-8-3-3

Source DB:  PubMed          Journal:  Methodist Debakey Cardiovasc J        ISSN: 1947-6108


  37 in total

1.  Bone marrow core biopsy specimens in AL (primary) amyloidosis. A morphologic and immunohistochemical study of 100 cases.

Authors:  Niall Swan; Martha Skinner; Carl J O'Hara
Journal:  Am J Clin Pathol       Date:  2003-10       Impact factor: 2.493

Review 2.  Molecular mechanisms of amyloidosis.

Authors:  Giampaolo Merlini; Vittorio Bellotti
Journal:  N Engl J Med       Date:  2003-08-07       Impact factor: 91.245

Review 3.  The systemic amyloidoses.

Authors:  R H Falk; R L Comenzo; M Skinner
Journal:  N Engl J Med       Date:  1997-09-25       Impact factor: 91.245

4.  How to manage primary amyloidosis.

Authors:  M A Gertz
Journal:  Leukemia       Date:  2011-08-26       Impact factor: 11.528

Review 5.  Dialysis-related amyloidosis: history and clinical manifestations.

Authors:  F Danesh; L T Ho
Journal:  Semin Dial       Date:  2001 Mar-Apr       Impact factor: 3.455

6.  A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.

Authors:  R A Kyle; M A Gertz; P R Greipp; T E Witzig; J A Lust; M Q Lacy; T M Therneau
Journal:  N Engl J Med       Date:  1997-04-24       Impact factor: 91.245

7.  Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo.

Authors:  R A Kyle; P R Greipp
Journal:  Blood       Date:  1978-10       Impact factor: 22.113

8.  Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis.

Authors:  Helen J Lachmann; David R Booth; Susanne E Booth; Alison Bybee; Janet A Gilbertson; Julian D Gillmore; Mark B Pepys; Philip N Hawkins
Journal:  N Engl J Med       Date:  2002-06-06       Impact factor: 91.245

Review 9.  The hereditary amyloidoses.

Authors:  Merrill D Benson
Journal:  Best Pract Res Clin Rheumatol       Date:  2003-12       Impact factor: 4.098

10.  Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.

Authors:  Angela Dispenzieri; Morie A Gertz; Robert A Kyle; Martha Q Lacy; Mary F Burritt; Terry M Therneau; Philip R Greipp; Thomas E Witzig; John A Lust; S Vincent Rajkumar; Rafael Fonseca; Steven R Zeldenrust; Christopher G A McGregor; Allan S Jaffe
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

View more
  19 in total

1.  Primary amyloidosis mimicking Crohn's disease: a case report.

Authors:  Ziwei Wang; Chaoyang Huang; Feng Ji
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 2.  Fibrinogen alpha amyloidosis: insights from proteomics.

Authors:  Jessica Chapman; Ahmet Dogan
Journal:  Expert Rev Proteomics       Date:  2019-08-28       Impact factor: 3.940

Review 3.  Differential diagnosis of T2 hypointense masses in musculoskeletal MRI.

Authors:  Dara Finkelstein; Gregory Foremny; Adam Singer; Paul Clifford; Juan Pretell-Mazzini; Darcy A Kerr; Ty K Subhawong
Journal:  Skeletal Radiol       Date:  2021-03-02       Impact factor: 2.199

4.  Aggregates Sealed by Ions.

Authors:  Giovanni La Penna; Silvia Morante
Journal:  Methods Mol Biol       Date:  2022

5.  Interactions between S100A9 and Alpha-Synuclein: Insight from NMR Spectroscopy.

Authors:  Zigmantas Toleikis; Raitis Bobrovs; Agne Janoniene; Alons Lends; Mantas Ziaunys; Ieva Baronaite; Vytautas Petrauskas; Kristine Kitoka; Vytautas Smirnovas; Kristaps Jaudzems
Journal:  Int J Mol Sci       Date:  2022-06-17       Impact factor: 6.208

Review 6.  Epidemiology and clinical manifestations of cardiac amyloidosis.

Authors:  Farhan Bajwa; Ryan O'Connor; Karthikeyan Ananthasubramaniam
Journal:  Heart Fail Rev       Date:  2021-10-25       Impact factor: 4.654

Review 7.  Lessons learned from protein aggregation: toward technological and biomedical applications.

Authors:  César L Avila; Silvina Chaves; Sergio B Socias; Esteban Vera-Pingitore; Florencia González-Lizárraga; Cecilia Vera; Diego Ploper; Rosana Chehín
Journal:  Biophys Rev       Date:  2017-09-13

Review 8.  Amyloid and the Heart.

Authors:  Aaron M Wolfson; Kevin S Shah; Jignesh K Patel
Journal:  Curr Cardiol Rep       Date:  2019-12-03       Impact factor: 2.931

9.  Shear wave elastography evaluation of liver, pancreas, spleen and kidneys in patients with familial mediterranean fever and amyloidosis.

Authors:  Zuhal Bayramoglu; Zeynep Nur Akyol Sari; Oya Koker; Ibrahim Adaletli; Rukiye Eker Omeroglu
Journal:  Br J Radiol       Date:  2021-09-14       Impact factor: 3.039

10.  Use of a Daratumumab-Specific Immunofixation Assay to Assess Possible Immunotherapy Interference at a Major Cancer Center: Our Experience and Recommendations.

Authors:  Daniel C Kirchhoff; Kazunori Murata; Katie L Thoren
Journal:  J Appl Lab Med       Date:  2021-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.